How much revenue does Bloomios make?

Bloomios reported $6.08 million in revenue for fiscal year 2022, down 28.4% from $8.49 million in fiscal year 2021. In Q3 2023 revenue was $682,036.

What companies are similar to Bloomios?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Legacy Technology Holdings, Inc. (LTHO), Petlife Pharmaceuticals, Inc. (PTLF), CanaFarma Hemp Products Corp. (CNFHF), Quick-Med Technologies, Inc. (QMDT).

Bloomios, Inc. (BLMS) Stock

About Bloomios, Inc.

Bloomios, Inc. manufactures, markets, and distributes cannabidiol products. The company's product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. It sells its hemp derived supplements and cosmetic products through wholesale and retail distribution channels. The company was formerly known as XLR Medical Corp. and changed its name to ...

At a glance

Bloomios reported revenue of $6.08 million for fiscal year 2022, down 28.4% from fiscal year 2021, and net income of -$13.77 million. In Q3 2023 (the quarter ended September 30, 2023) revenue was $682,036, down 43.1% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.